¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Complement Hemolytic Activity Assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • complement system
    º¸Ã¼°è, µµ¿òü°èÅë
  • complement-dependent cytotoxicity
    º¸Ã¼ÀÇÁ¸¼¼Æ÷µ¶¼º
  • complement-fixing antibody
    º¸Ã¼°áÇÕÇ×ü, µµ¿òü°áÇÕÇ×ü
  • complement-induced
    º¸Ã¼À¯µµ-
  • complement-mediated
    º¸Ã¼¸Å°³-
  • complement-mediated cytotoxicity
    º¸Ã¼¸Å°³¼¼Æ÷µ¶¼º
  • dominant complement
    ¿ì¼ºº¸Ã¼
  • antibacterial activity
    Ç×±ÕÀÛ¿ë
  • activity
    1. Ȱ¼ºµµ 2. Ȱµ¿, Ȱ¼º 3. -´É
  • biologic activity
    »ý¹°ÇÐÀûȰ¼º
  • caries activity
    ¿ì½ÄȰµ¿
  • electrical activity
    Àü±âȰ¼º
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • fibrinolytic activity
    ¼¶À¯¼Ò¿ëÇØ´É, ÇǺ기¿ëÇØ´É
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤¹ý, ÇöóÅ©ÃøÁ¤¹ý
  • radial partition immunofluorometric assay
    ¹æ»ç¼ººÐÇҸ鿪Çü±¤ÃøÁ¤
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
  • superoxide assay
    °ú»êÈ­¹°ÃøÁ¤
  • dilution assay technique
    Èñ¼®ºÐ¼®¹ý
  • hemizona assay index
    ¹ÝÅõ¸í¶ìÃøÁ¤ÁöÇ¥
  • activity
    Ȱ¼ºµµ, Ȱµ¿
  • activity therapist
    Ȱµ¿¿ä¹ý»ç, Ȱµ¿Ä¡·á»ç
  • activity therapy
    Ȱµ¿¿ä¹ý
  • alternative complement pathway
    º¸Ã¼´ëü°æ·Î, µµ¿òü´ëü°æ·Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activity
    ¹æ»ç´É, Ȱ¼ºµµ
  • activity therapist
    Ȱµ¿ ¿ä¹ý»ç
  • activity therapy
    Ȱµ¿¿ä¹ý(¡­èþÛö).
  • activity therapy
    Ȱµ¿ ¿ä¹ý
  • activity, antibacterial
    Ç×±ÕÀÛ¿ë
  • amylase activity
    ¾Æ¹Ð¶óÁ¦-Ȱ¼ºµµ
  • antibacterial activity
    Ç×±ÕÀÛ¿ë(ù÷жíÂéÄ), Ç×±ÕȰ¼º(ù÷жüÀàõ).
  • functional activity
    ±â´É¼º Ȱ¼ºµµ<Ȱµ¿µµ>
  • fusion activity
    À¶ÇÕ´É
  • glucagon activity
    ±Û·çÄ«°ïȰ¼ºµµ.
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • homosexual activity
    µ¿¼º¾ÖÀû ÇàÀ§
  • plasma histaminase activity
    Ç÷ÀåÈ÷½ºÅ¸¹Ì³ª¾ÆÁ¦È°¼ºµµ.
  • plasma renin activity
    Ç÷Àå·¹´ÑȰ¼ºµµ<--Ȱµ¿µµ>
  • psychomotor activity
    Á¤½Å¿îµ¿¼º Ȱµ¿.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • binding activity
    °áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • binding activity
    ¸é¿ª°áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • caries activity
    ¿ì½ÄȰµ¿¼º(ó»ãÚüÀÔÑàõ), ¿ì½ÄȰµ¿µµ(¡­öô).
  • displacement activity
    ÀüġȰµ¿
  • effect concentration(=activity)
    À¯È¿³óµµ(êóüùÒØÓø)
  • elastolytic activity
    ¿¤¶ó½ºÆ¾¿ëÇØÈ°¼º(µµ), ¿¤¶ó½ºÅ¸¾ÆÁ¦È°¼º(µµ).
  • enzyme activity
    È¿¼ÒȰ¼º
  • enzyme activity
    È¿¼ÒȰ¼ºµµ
  • epidemiologic activity
    ¿ªÇÐÀû Ȱµ¿(ËçÌ°Ëø Ì·ËÄ).
  • fibrinolytic activity
    ¼¶À¯¼Ò¿ëÇØ´É
  • functional activity
    ±â´É¼º Ȱ¼ºµµ<Ȱµ¿µµ>
  • fusion activity
    À¶ÇÕ´É
  • glucagon activity
    ±Û·çÄ«°ïȰ¼ºµµ.
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • homosexual activity
    µ¿¼º¾ÖÀû ÇàÀ§
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • indirect complement fixation test
    °£Á¢º¸Ã¼°íÁ¤½ÃÇè(ÊàïÈÜÍô÷ͳïÒãËúÐ)
  • activity
    Ȱ·®(üÀÕá)
  • activity
    Ȱ¼º (üÀàõ)
  • activity coefficient
    Ȱ·®°è¼ö (üÀÕá°èâ¦)
  • catalytic center activity
    Ã˸ÅÁß½É È°¼º(õºØÚñéãýüÀàõ)
  • concentration of enzymatic activity
    È¿¼ÒȰ¼º ³óµµ(ý£áÈüÀàõÒØÓø)
  • enzymatic activity
    È¿¼Ò Ȱ¼º (ý£áÈüÀàõ)
  • intrinsic activity
    ³»ÀçȰ¼º(Ò®î¤üÀàõ)
  • mean activity coefficient
    Æò±ÕȰµ¿°è¼ö(øÁгüÀÔÑͪâ¦)
  • mean ionic activity coefficient
    Æò±Õ(øÁг) ÀÌ¿ÂȰ¼º°è¼ö(üÀàõͪâ¦)
  • molar activity
    ¸ô Ȱ¼º(üÀàõ)
  • molecular activity
    ºÐÀÚȰ¼º(ÝÂí­üÀàõ)
  • myotropic activity
    ±Ù°­È­È°¼º(ÐÉË­ûùüÀàõ)
  • optical activity
    ±¤ÇРȰ¼º(ÎÃùÊüÀàõ)
  • Raman optical activity
    ¶ó¸¸ ±¤ÇРȰ¼º(µµ)(ÎÃùÊüÀàõ(Óø))
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TGA taurocholate gelatin agar; thyroglobulin activity; total glycoalkaloids; total gonadotropin activity...
MAHA Micro-Angiopathic Hemolytic Anemia; PB»ó Helmet Cell
  ThrombocytopeniaÁß MAHAÀ¯¹ß
&nbs...
PrA-HPA protein A hemolytic plaque assay
ISA Instrument Society of America; intracarotid sodium amytal; intrinsic simulating activity; intrinsic ...
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GBS Group B beta--hemolytic streptococcus
HTR Hemolytic transfusion reactions
MAHA Microangiopathic hemolytic anemia
TTP-HUS Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
ACP Alternative complement pathway
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • assay
    Á¤·®, ¿ª°¡ °ËÁ¤, È¿·Â °ËÁ¤
    È¥ÇÕ¹°¿¡ ÀÖ´Â ¼ººÐÀÇ ¾ç, ¶Ç´Â ¾à¹°ÀÇ »ý¹°ÇÐÀû, ¾à¸®ÇÐÀû ¿ª°¡ µîÀÇ ÃøÁ¤.
  • autoimmune hemolytic disease
    ÀÚ°¡ ¸é¿ª¼º ¿ëÇ÷¼º Áúȯ
  • calcitonin assay
    Ä®½ÃÅä´Ñ ÃøÁ¤
  • carcinoembryonic antigen assay
    ¾Ï ¹è¾Æ¼º Ç׿ø ÃøÁ¤, ¾Ï¼º ¹è¾Æ¼º Ç׿ø ÃøÁ¤
  • carcinogen assay
    ¹ß¾Ï ¹°Áú °Ë»ç
  • cell adhesive matrix assay
    ¼¼Æ÷ Á¡Âø ±âÁú ºÐ¼®
  • colony formation assay
    Áý¶ô Çü¼º´É ÃøÁ¤
  • congenital hemolytic anemia
    ¼±Ãµ¼º ¿ëÇ÷¼º ºóÇ÷
    ÈÄõ¼º ¿ëÇ÷¼º ºóÇ÷¿¡ ´ëÀÀÇÏ¿©, ÀûÇ÷±¸ÀÇ ¼±ÃµÀûÀÎ ´ë»ç ÀÌ»ó¿¡ ÀÇÇØ ÀϾ´Â ¿ëÇ÷¼º ºóÇ÷ÀÇ ÃÑĪÀÌ´Ù. ±× ¿øÀÎÀº ¨ç ÀûÇ÷±¸ ¸· ÀÌ»ó¿¡ ÀÇÇÑ °Í
  • drug-induced hemolytic anemia
    ¾à¹°¼º ¿ëÇ÷¼º ºóÇ÷, ¾àÁ¦ À¯¹ß¼º ¿ëÇ÷¼º ºóÇ÷
  • enzymatic assay
    È¿¼Ò¼º ÃøÁ¤, È¿¼Ò¼º ÃøÁ¤¹ý
  • enzyme-linked immunoadsorbent assay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
  • enzyme-linked immunosorbent assay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
  • familial hemolytic anemia
    °¡Á·¼º ¿ëÇ÷¼º ºóÇ÷
  • hemolytic
    ¿ëÇ÷¼º
    ÀûÇ÷±¸°¡ ½±°Ô ÆÄ±«µÇ¾î Çì¸ð±Û·ÎºóÀÌ Ç÷±¸ ¹ÛÀ¸·Î ºüÁ® ³ª¿À´Â.
  • hemolytic antibody
    ¿ëÇ÷ Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
structure activity analysis Study in which systematic variation in the structure of a compound is correlated with its activity, in an attempt to determine the characteristics of the (receptor) site at which it acts.
(18 Nov 1997)
structure-activity relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Other factors contributing to structure-activity relationship include chemical reactivity, electronic effects, resonance, and inductive effects.
(12 Dec 1998)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
drug activity A measure of the physiological response a drug produces. A less active drug produces less response (and visa versa).
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
intrinsic sympathomimetic activity The property of a drug that causes activation of adrenergic receptors so as to produce effects similar to stimulation of the sympathetic nervous system.
(05 Mar 2000)
optical activity The ability of a material to rotate the plane of polarized light.
(09 Oct 1997)
triggered activity One or a series of spontaneously generated heart beats originating from an action potential that produces an after-depolarisation which reaches activation threshold.
(05 Mar 2000)
unit of thyrotrophic activity The activity of an amount of an extract of the anterior lobe of the hypophysis which, given daily for 5 days, will cause the thyroid of a guinea pig (weighing 200 g) to reach a weight of 600 mg.
(05 Mar 2000)
zone of polarizing activity <cell biology> The small group of mesenchyme cells in avian limb buds that is located at the posterior margin of the developing bud and that produces a substance, possibly retinoic acid, that provides positional information to the developing limb bud.
(18 Nov 1997)
male chromosome complement The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes).
(12 Dec 1998)
genetic complement <biology, genetics> The set of chromosomes contained within any one particular cell.
(07 May 1998)
receptors, complement Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement.
(12 Dec 1998)
receptors, complement 3b Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
(12 Dec 1998)
receptors, complement 3d Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á